← Volver a la portada
Américas · Actualidad general · Toronto Star

Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations

Publicado por Toronto Star · Canadá hace 9 h
Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations
Toronto Star

Resumen detallado

Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that data ...

Fremont, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that data generated with its NULISA™ precision proteomic platform will be featured in 46 presentations, including 10 oral presentations, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 16 to 19, 2026, in Boston.

The presentations come from researchers at academic centers, clinical research institutes and biopharmaceutical companies in the United States, Europe and Asia. Together they show NULISA being used at each stage of Alzheimer’s research, from identifying who is at risk and enrolling the right patients in clinical trials to measuring how patients respond to treatment.

Since its commercial launch in January 2024, Alamar’s NULISA technology has been cited in hundreds of research publications worldwide, including studies advancing the early detection, diagnosis, monitoring and treatment of Alzheimer’s disease.

“Given the advances in blood-based biomarkers for diagnosing Alzheimer’s, research is shifting toward treatment, and that shift depends on measuring many proteins in blood with enough sensitivity to see small changes over time,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “This year’s CTAD presentations show researchers using NULISA to screen patients, enrich clinical trials and follow therapeutic response, often in the same study. The breadth of this work reinforces NULISA’s position as the leading multiplex platform in Alzheimer’s research. We are grateful to our collaborators for this work and for what it means for the patients who will benefit from it.”

“Blood biomarkers have transformed how we diagnose Alzheimer’s disease and conduct clinical trials. With the development of an ultrasensitive singleplex assay for plasma eMTBR-tau, we are moving closer to characterizing the two fundamental pathological…

Inicio del artículo, extracto de Toronto Star. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Toronto Star Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.thestar.com)

También te puede interesar